Recent news on Tipranavir

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 12, 2007
Medical News Today (press release),Apart from Viramune® (nevirapine), Aptivus® (tipranavir) is a new non-peptidic protease inhibitor, approved for combination antiretroviral treatment of

Boehringer Ingelheim Initiates International Head-to-Head HIV/AIDS ...  -  May 9, 2007
campus med,Apart from Viramune(R) (nevirapine), Aptivus(R) (tipranavir) is a new non-peptidic protease inhibitor, approved for combination antiretroviral treatment of

Darunavir Effective in Resistant HIV  -  Apr 5, 2007
MedPage Today,It is also not clear, he said, how darunavir compares in this population with tipranavir (Aptivus), another relatively new protease inhibitor boosted with

TMC125 Can Be Used in Combination with Most Antiretrovirals  -  Apr 12, 2007
Drug Newswire (press release),Tipranavir/ritonavir, nevirapine and efavirenz reduced TMC125 exposures by 76%, 55% and 41% and should not be used in combination with TMC125.

Promising New Treatment for HIV  -  Apr 5, 2007
DG NewsA comparison of darunavir-ritonavir with tipranavir-ritonavir (an existing therapy) would also be needed, as some cross resistance can occur between the two

Darunavir looking promising as companion for agents in new HIV ...  -  Apr 4, 2007
Aidsmap,...with PI failure showed that the risk of cross-resistance to darunavir was highest after the failure of tipranavir/ritonavir or fosamprenavir/ritonavir.

New HIV drug shows promise  -  Apr 4, 2007
CBC North,Darunavir-ritonavir also needs to be compared with an existing therapy, tipranavir-ritonavir, since resistance to one could fuel resistance to the other.

Gilead integrase inhibitor found to suppress HIV  -  Feb 28, 2007
Reuters...due to lack of effectiveness and at the same time patients were allowed to add protease inhibitors darunavir and tipranavir to their drug regimens.

CROI: Experimental 'salvage' integrase inhibitor, elvitegravir (GS ...  -  Mar 6, 2007
Aidsmap,...been completed at the start of the trial suggested that there were no significant interactions between elvitegravir and either darunavir or tipranavir.

Gilead Announces 24-Week Results from Phase II Study of ...  -  Mar 2, 2007
PharmaLive.com (press release),The addition of darunavir or tipranavir to the GS 9137 study arms was also permitted at week eight following the availability of data demonstrating a lack

HIV market: collaborative combinations  -  Mar 13, 2007
Pharmaceutical Business ReviewThe new, so-called non-peptidic Protease Inhibitors (PIs) such as Aptivus (tipranavir, Boehringer Ingelheim) and Prezista (Darunavir, Tibotec) are obvious

New era of HIV/AIDS treatment on the horizon  -  Mar 9, 2007
pride source.com,..."Even though we have new protease drugs like Tipranavir and Darunavir, there are already large numbers of patients who have the virus which is partly

Get the latest news direct to your desktop  -  Mar 2, 2007
PipelineReview.com (press release),In order to allow for the best possible treatment regimen to be constructed for each patient, darunavir and tipranavir, which were investigational ARTs in

CROI: Maraviroc shows potent effect in highly treatment-experienced  -  Feb 27, 2007
Aidsmap,Individuals taking a ritonavir-boosted protease inhibitor other than tipranavir, or the NNRTI delavirdine (which is not licensed in the UK), were provided

Officials at Boehringer Ingelheim discuss recent developments  -  Feb 8, 2007
Therapeutics Daily (subscription) (press release),Report 1: Data from two 24-week analyses of the RESIST-1 and RESIST-2 studies, which evaluated Aptivus (tipranavir) in treatment-experienced HIV-1 infected

Panacos Reports Fourth Quarter and Full Year 2006 Financial Results  -  Feb 21, 2007
Business Wire (press release),...clinical development program and regulatory review process for the HIV protease inhibitor tipranavir (APTIVUS) at Boehringer Ingelheim Pharmaceuticals.

Data Published In AIDS Show Viramune (nevirapine) Achieves Durable ...  -  Feb 5, 2007
Medical News Today (press release),Apart from Viramune, Aptivus (tipranavir) is a new non-peptidic protease inhibitor, approved for combination antiretroviral treatment of HIV-1 infected

Data Published in AIDS Show Viramune(R) (nevirapine) Achieves ...  -  Jan 31, 2007
Juraforum.de,Apart from VIRAMUNE(R), APTIVUS(R)(tipranavir) is a new non-peptidic protease inhibitor, approved forcombination antiretroviral treatment of HIV-1 infected

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  Dec 26, 2006
Medscape (subscription)Tipranavir. Resistance to tipranavir has been a matter of controversy for a long time. Preliminary data led the drug's manufacturer to suspect that 4

Strategies for coping with multiple drug resistance  -  Dec 20, 2006
NAPWA,Tipranavir has been around a bit longer than darunavir, and has been used in a larger number of patients worldwide. Pau noted some of the factors associated

After 48 weeks of study, and 24 weeks in the real world, darunavir ...  -  Dec 21, 2006
Aidsmap,...prior antiretrovirals); more than 95% had burned through three or more PIs – including tipranavir for one in three – and 39% had previously taken T-20.

Antiretroviral Therapy for HIV: New Data From HIV 8 in Glasgow  -  26 Dec 2006
Medscape (subscription)Tipranavir. Resistance to tipranavir has been a matter of controversy for a long time. Preliminary data led the drug's manufacturer to suspect that 4

Strategies for coping with multiple drug resistance  -  Dec 20, 2006
NAPWA,Tipranavir has been around a bit longer than darunavir, and has been used in a larger number of patients worldwide. Pau noted some of the factors associated

J&J files NDA for doripenem  -  Dec 18, 2006
Pharma Times (subscription),The drug received approval in the USA at the end of June and is expected to go up against Boehringer Ingelheim's Aptivus (tipranavir).

After 48 weeks of study, and 24 weeks in the real world, darunavir ...  -  Dec 21, 2006
Aidsmap,...prior antiretrovirals); more than 95% had burned through three or more PIs – including tipranavir for one in three – and 39% had previously taken T-20.

Prezista (darunavir) approved for treatment-experienced patients ...  -  Dec 15, 2006
Aidsmap,...says its manufacturer Tibotec, and is likely to replace its less well tolerated competitor tipranavir (Aptivus) as the salvage therapy drug of choice.

Aptivus®(tipranavir) Demonstrates Durable Response Through Nearly ...  Oct 15, 2006
New data from a 96-week combined analysis of RESIST-1 and RESIST-2 show that Aptivus® (tipranavir) provides a superior and durable treatment response in ... -Medical News Today (press release), Antiretroviral Drug Resistance in Patients With HIV  Nov 6, 2006
Several ICAAC presentations addressed the use of the 2 newest PIs, tipranavir (TPV) and darunavir (TMC-114, DRV), for therapy in highly treatment-experienced ... -Medscape (subscription) FDA Safety Changes: Aptivus, Celestone, Celestone Soluspan  Nov 1, 2006
November 1, 2006 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to advise that ritonavir-boosted tipranavir therapy may ... -Medscape (subscription) Antiretroviral Treatment Strategies for Adults With HIV  Nov 2, 2006
...[1] The PI tipranavir (TPV), given twice daily with RTV, has recently been approved for the management of patients with drug-resistant virus. ... -Medscape (subscription) ICAAC 2006 - The Anti-HIV Drug Pipeline CME  Nov 6, 2006
Following on the footsteps of the 2 recently approved protease inhibitors, tipranavir and darunavir, the pipeline continues to advance new agents in existing ... -Medscape (subscription) A Step Ahead of Resistance; Virco Introduces an Improved Rapid ...  Oct 16, 2006
...recently introduced an improved virco(R)TYPE HIV-1 test that rapidly determines the complex phenotypic resistance profiles for darunavir, tipranavir and other ... -PR Newswire (press release), FUZEON Combined With New Investigational HIV Drug Results in ...  Oct 9, 2006
..."Today, we already see that using FUZEON with darunavir or tipranavir, we have the right drugs to help us achieve the treatment goal of undetectable viral load ... -Drug Newswire (press release), Panacos Appoints Scott McCallister, MD, Chief Medical Officer  Nov 1, 2006
At BI, Dr. McCallister coordinated the design, conduct, and analysis of more than 20 Phase I, II, and III tipranavir development trials, culminating in the FDA ... -Business Wire (press release), A Step Ahead of Resistance; Virco Introduces an Improved Rapid ...  Oct 16, 2006
The improvements in virco(R)TYPE HIV-1 "helps clinicians evaluate resistance to darunavir, tipranavir, and other ARV drugs, and assists them in constructing ... -Earthtimes.org Darunavir response did not differ by prior PI in POWER studies  Oct 8, 2006
Specific comparisons were made between those whose previous (failing) regimen had contained tipranavir (TPV), lopinavir (LPV), and fosamprenavir (fAPV). ... -Aidsmap, FDA Announces Revised Adult HIV Treatment Guidelines  Oct 11, 2006
Atripla(tm)) and new safety information and black box warnings regarding rare cases of intracranial hemorrhages occurring in patients receiving tipranavir. ... -PharmaLive.com (press release), New HIV Drug Accepted By Scottish Medicines Consortium  Sep 13, 2006
HIV patients in Scotland with high levels of resistance to protease inhibitors could soon benefit from treatment with tipranavir boosted with ritonavir ... -Medical News Today

Antiretroviral Treatment Strategies for Adults  Sep 22, 2006
...with darunavir. More data are needed regarding the long-term efficacy and safety of this PI, as we have learned from tipranavir. In ... -Medscape (subscription)

Draft BHIVA treatment guidelines: respond by Monday September 4 th  Aug 30, 2006
The guidelines discuss the recent data on boosted tipranavir (Aptivus and boosted darunavir (TMC-114, Prezista in the United States where it was approved in ... -Aidsmap

Tipranavir falls between two stools in naïve trial  -  Nov 20, 2006
Aidsmap,An analysis of a trial comparing the protease inhibitor tipranavir (Aptivus) with lopinavir/ritonavir (Kaletra) as a first-line therapy was stopped after 60

Long-Term Data Show Aptivus(R) (tipranavir) Continues to ...  -  Nov 15, 2006
Drug Newswire (press release),1) Further, a sub-analysis shows that tipranavir/r scored higher in quality of life measures compared to other protease inhibitors.

Long-Term Data Show Tipranavir Continues to Outperform Group of ...  -  Nov 15, 2006
DG NewsFurther, a sub-analysis shows that tipranavir/r scored higher in quality of life measures compared to other protease inhibitors.2 These data were presented

Long-Term Data Show Aptivus(R) (tipranavir) Continues to ...  -  Nov 14, 2006
Earthtimes.org1) Further, a sub-analysisshows that tipranavir/r scored higher in quality of life measures compared toother protease inhibitors.

24-week Results From Aptivus® (tipranavir) RESIST Studies ...  -  Nov 22, 2006
Medical News Today (press release),Data from two 24-week analyses of the RESIST-1 and RESIST-2 studies, which evaluated Aptivus® (tipranavir) in treatment-experienced HIV-1 infected patients,

HIV needs many more mutations to acquire resistance to darunavir  -  Nov 21, 2006
Aidsmap,Darunavir mutations confer resistance to most other PIs including lopinavir and fosamprenavir, but there is limited cross-resistance with tipranavir;

Is HIV drug resistance in decline in Europe?  -  Nov 17, 2006
Aidsmap,...whose genotype indicated susceptibility to no more than one HIV antiretroviral, with the exceptions of enfuvurtide (T-20), tipranavir and darunavir.

TMC125 Can Be Used in Combination with Most Antiretrovirals  -  Nov 15, 2006
campus med,Tipranavir/ritonavir, nevirapine and efavirenz reduced TMC125 exposures by 76%, 55% and 41% and should not be used in combination with TMC125.

(PRN) - Amtrak Wins dabs.com Contract ... [+]  -  Nov 15, 2006
Bolsamania.com,...(PRN) - Long-Term Data Show Aptivus(R) (tipranavir) Continues to Outperform Group of Protease Inhibitors in RESIST Trials ... [+]

COMUNICADO: Tipranavir Achieves Virologic and Immunologic ...  Aug 14, 2006
New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were announced today at the 16th ... -Europa Press

Oral solution of tipranavir/ritonavir shows promise for treatment ...  Aug 16, 2006
An investigational oral solution of the protease inhibitor tipranavir (Aptivus), boosted by ritonavir, has a potent anti-HIV effect and is generally well ... -Aidsmap

Tipranavir Oral Solution With Low-Dose Ritonavir Effective and ...  Aug 21, 2006
TORONTO, CANADA -- August 21, 2006 -- Tipranavir oral solution with low-dose ritonavir shows clinically relevant virologic and immunologic improvements in HIV ... -DG News

The Lancet Publishes 48-week Results From Tipranavir RESIST ...  Aug 8, 2006
GERMANY -- August 8, 2006 -- Data from a 48-week combined analysis of the RESIST-1 and RESIST-2 studies, which evaluated Aptivus® (tipranavir) in treatment ... -DG News

Tipranavir Achieves Virologic and Immunologic Improvements in HIV ...  Aug 14, 2006
Toronto (ots/PRNewswire) - New data on tipranavir oral solution from a Phase II dose finding study in 115 HIV-1 infected children aged 2 to 18 years were ... -news aktuell (Pressemitteilung)

Experimental Antiretroviral Combination Therapy Effective in ...  Aug 16, 2006
...pharmaceutical company Boehringer Ingelheim's experimental oral formulation of its antiretroviral drug Aptivus, known generically as tipranavir, in combination ... -Kaiser network.org

COMUNICADO: Updated International AIDS Society Guidelines ...  Aug 14, 2006
...to achieve this goal, in this difficult-to- treat clinical patient population, is to combine FUZEON with new HIV agents such as darunavir/r or tipranavir/r[1]. ... -Europa Press

New HIV guidelines recommend Roche's Fuzeon  Aug 15, 2006
...is to combine Roche and Trimeris' Fuzeon with new HIV agents such as darunavir boosted with low-dose ritonavir (darunavir/r) or tipranavir boosted with low ... -PharmaLeader

Boehringer ingelheim  Aug 14, 2006
...tipranavir/r twice daily. Doses of tipranavir/r for children were based on body surface. ... The 12- to. Tipranavir/r was well tolerated in this study. ... -ANP Pers Support

New Treatment Guidelines Support Use of FUZEON(R) to Achieve ...  Aug 14, 2006
HIV (less than 50 copies/mL), and highlight theresults from several pivotal studies with newer anti-HIV treatments,such as darunavir and tipranavir, in which ... -Finanzen.net

Analysis: Aim high, new AIDS rules say  Aug 14, 2006
Hammer, the lead author of the guidelines, said the approval of the protease inhibitor tipranavir (Aptivus) and darunavir (Prezista), also known as TMC114 ... -Monsters and Critics.com

Sector Wrap: HIV Drugs in the Spotlight  Aug 18, 2006
...countries. German drug maker Boehringer Ingelheim also unveiled a study of its HIV drug Tipranavir for use in infected children. ... -Houston Chronicle

IAC: Pediatric HIV Drug Seen Safe and Effective  Aug 17, 2006
The oral solution of Aptivus (tipranavir) boosted with Norvir (ritonavir) adds to the options for HIV-positive children and adolescents with a history of ... -MedPage Today

HIV - Updated Information On Aptivus® (tipranavir) Clinical Trial ...  Jul 9, 2006
Over the course of all clinical trials with Aptivus® (tipranavir) capsules in anti-HIV combination treatment, Boehringer Ingelheim has received 14 reports of ... -Medical News Today

Tipranavir study halted in treatment-naive  Jun 21, 2006
Boehringer-Ingelheim has halted a three-year study of its new protease inhibitor tipranavir (Aptivus) in treatment-naïve patients because tipranavir-treated ... -Aidsmap

Warning issued over bleeding within the skull in patients taking ...  Jul 3, 2006
Tipranavir (Aptivus) may be associated with an increased risk of bleeding within the skull when boosted with low-dose ritonavir (Norvir), according to a ... -Aidsmap

Health News Briefs  Jul 5, 2006
At least eight patients died from intra-cranial bleeding after taking the protease inhibitor Aptivus, which is generally known as tipranavir. ... -NPR

New label on HIV drug to warn of bleeding  Jun 30, 2006
The new warnings recommend doctors use caution in prescribing Aptivus, also known as tipranavir, to patients at risk for increased bleeding. ... -San Jose Mercury News

US FDA Approval of Boosted Protease Inhibitor Enables Potent New ...  Jun 23, 2006
...patients to achieve undetectable levels of HIV.Data from the FUZEON pivotal trials, TORO 1 and TORO 2, as well as theRESIST studies with tipranavir/r have ... -Finanzen.net

US FDA Approval of Boosted Protease Inhibitor Enables Potent New ...  Jun 23, 2006
Data from the FUZEON pivotal trials, TORO 1 and TORO 2, as well as the RESIST studies with tipranavir/r have consistently validated this approach. ... -Genetic Engineering News

Tibotec and J&J Cleared to Launch Aptivus Rival  Jun 29, 2006
It is the second so-called non-peptidic PI to reach the market, the first being Boehringer Ingelheim's Aptivus (tipranavir), which was launched in June 2005 in ... -International News Service

FDA Updates Black Box Warning on Boehringer Ingelheim's Protease ...  Jul 3, 2006
The approved dosage of Aptivus, which is known generically as tipranavir, is 500 milligrams in combination with 200 milligrams of Norvir, which is known ... -Kaiser network.org

New Addition to Aptivus Black Box Warning  Jul 3, 2006
...professionals are being informed by the FDA and Boehringer Ingelheim of an addition to the Black Box Warning of Aptivus (tipranavir) capsules regarding reports ... -Facts and Comparisons

US activists 'applaud' darunavir (Prezista, TMC114) pricing  Jun 29, 2006
The company announced last week that the drug will cost less than tipranavir (Aptivus) and is priced virtually the same as atazanavir (Reyataz), representing a ... -Aidsmap

First approval for Tibotec's HIV drug Prezista  Jun 26, 2006
...inhibitor experienced HIV patients, a group which has been a particular focus of treatment with Boehringer Ingelheim's Aptivus (tipranavir), approved in Europe ... -Pharma Times (subscription)



Efficacy of TMC114/r in Treatment-experienced HIV Patients ...  Apr 4, 2006
...said to be consistent with previously completed studies in highly treatment-experienced patients, such as RESIST I and II, which evaluated tipranavir, and TORO ... - DG News



Boehringer Ingelheim Announces 48-week Results from Aptivus ...  Feb 10, 2006
RIDGEFIELD, CN -- February 10, 2006 -- New data on Aptivus(R) (tipranavir) capsules from a 48-week combined analysis of the RESIST-1 and RESIST-2 studies were ... - DG News

Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ...  Feb 9, 2006
9 /PRNewswire/ -- New data on Aptivus(R) (tipranavir) capsules from a 48-week combined analysis of the RESIST-1 and RESIST-2 studies were presented at the 13th ... - PR Newswire,

New Data on Tibotec HIV/AIDS Investigational Product Portfolio  Feb 16, 2006
Additionally, a study investigating the interactions between TMC125 and tipranavir showed a significant decrease of TMC 125 exposure. (Scholler et al). ... - PharmaLive.com,

Boehringer Ingelheim Announces 48-week Results from Aptivus(R) ...  09 Feb 2006
9 /PRNewswire/ -- New data on Aptivus(R) (tipranavir) capsules from a 48-week combined analysis of the RESIST-1 and RESIST-2 studies were presented at the 13th ... - PR Newswire

(PRN) - Specialty Metals Industry Group Releases Eleven-Month ...  09 Feb 2006
Conference ... [+. PRN) - Boehringer Ingelheim Announces 48-week Results from Aptivus(R) (tipranavir) RESIST Studies ... [+. PRN ... - Bolsamania.com

Roche and Trimeris Announce Selection of Two Next Generation HIV ...  Jan 19, 2006
Latest data adds to growing Body of Evidence - Latest Boosted Protease Inhibitors (lopinavir/r, tipranavir/r and the investigational agent TMC 114/r) all work ... - APA OTS (Pressemitteilung)

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional